Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2000 December;41(6) > The Journal of Cardiovascular Surgery 2000 December;41(6):935-9

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

ORIGINAL ARTICLES  THORACIC PAPERS 

The Journal of Cardiovascular Surgery 2000 December;41(6):935-9

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

A randomized trial of postoperative CDDP-based chemotherapy-chemoradiotherapy vs short-term immunochemotherapy in lung cancer

Sagawa M., Sato M., Fujimura S., Usuda K. *, Kondo T., Tanita T., Takahashi S. *, Ono S., Matsumura Y., Handa M. *, Saito Y. **

From the Department of Thoracic Surgery Institute of Development, Aging and Cancer Tohoku University, *Department of Surgery Sendai Kosei Hospital **Department of Thoracic Surgery National Sendai Hospital**, Sendai, Japan


PDF


Background. Although a few ­reports indi­cat­ed ­some ben­e­fit to sur­vi­val, the ­effect of adju­vant ther­a­py for the ­patients ­with resect­ed ­lung can­cer was ­still con­tro­ver­sial. The aim of our ­study was to eval­u­ate sur­vi­val advan­tage of ­CDDP-­based adju­vant ther­a­py com­pared ­with ­short-­term immu­noch­e­mo­ther­a­py.
Methods. Experimental ­design: pros­pec­tive ran­dom­ized ­trial. Patients: ­from 1990 ­through 1994, 94 ­patients ­were reg­is­tered. Forty-sev­en ­patients ­were ran­dom­ly ­assigned to ­each ­group, i.e., ­CDDP-­based ther­a­py ­group (CB Group, ­CDDP+VDS+teg­a­fur+OK-432 or ­CDDP+OK-432+med­i­as­ti­nal irra­di­a­tion) or immu­noch­e­mo­ther­a­py ­group (IC Group, teg­a­fur+OK-432). Patients in ­both ­groups ­were fol­lowed at 4-­month inter­vals ­with the rou­tine fol­low-up pro­gram of our depart­ment.
Results. No sig­nif­i­cant dif­fer­ence was ­observed ­between the ­patients’ char­ac­ter­is­tics of two ­groups. Compliance of the reg­i­men in ­each ­group was 79% in CB Group and 85% in IC Group. No treat­ment-relat­ed ­death was ­observed. Five-­year sur­vi­val ­rates of CB Group and IC Group ­were 49% and 51%, and 5-­year dis­ease-­free sur­vi­val ­rates ­were 46% and 44%, respec­tive­ly. There ­were no sta­tis­ti­cal dif­fer­enc­es ­between the two ­groups. Furthermore, no sur­vi­val dif­fer­enc­es ­could be ­found ­between CB Group and IC Group in any sub­group of ­patients.
Conclusions. Both of ­these reg­i­mens ­were fea­sible. However, we ­have not ­observed any sur­vi­val ben­e­fit in the CB Group in any sub­group, so far. Induction ther­a­py, new chem­o­ther­a­peu­tic ­agents, or ­anti-angiog­e­net­ic ­agents may ­improve the sur­vi­val of sur­gi­cal­ly treat­ed ­lung can­cer ­patients.

top of page